Andere Sprachen Portage Biotech Inc.

Aktien

A40HBS

VGG7185A1369

PRTG

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 13.06.2025			% 5 Tage	% 1. Jan.
5.990 ^USD	-5.07%		-28.78%	+15.86%

28.04.	Top-Gewinner zur Mittagszeit	MT
28.04.	Gewinnflut erwartet, während Aktien-Futures vor Börsenbeginn schwanken	MT

Andere Sprachen

Portage Biotech and Compedica Stock-for-Stock Exchange	09.06.
Top Midday Gainers	28.04.
Earnings Deluge Eyed as Equity Futures Waver Pre-Bell	28.04.
Top Premarket Gainers	28.04.
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7	28.04.
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of Port-7	28.04.
Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics	31.03.
Top Midday Gainers	28.03.
Wall Street Set to Open Lower Friday as Inflation Rises More Than Expected	28.03.
Top Premarket Gainers	28.03.
Investors Await Key Inflation Data as US Futures Decline Pre-Bell	28.03.
Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma	28.03.
Portage Reports 'Promising' Preclinical Results in Mesothelioma	27.03.
Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7	27.03.
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7	27.03.
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of Port-7	27.03.
Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments	12.03.
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial	12.03.
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial	12.03.
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements	12.02.
Portage Biotech Announces Completion of $2.15 Million Private Financing	30.01.
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company, Appointment of Peter Molloy to Lead New Company	07.01.
Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc	06.01.
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company	06.01.
Top Premarket Decliners	18.12.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Portage Biotech Inc.

Aktien

A40HBS

VGG7185A1369

PRTG

Biotechnologie

Andere Sprachen

Filter